Search clinical trials for: Tricyclodecane-9-yl-xanthogenate

Total 26 results

KARE Biosciences
Biomedical Advanced Research and Development Authority; BioLink Life Sciences... and other collaborators

Recruiting

Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia

COVID-19 Pneumonia | COVID-19 Respiratory Infection

India
NanoBio Corporation

Completed

Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis

Herpes Labialis

United States
Memorial Sloan Kettering Cancer Center

Completed

The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

Lymphoma | Metastatic Solid Tumor | Myeloproliferative Neoplasms (MPN)

United States
National Cancer Institute (NCI)

Terminated

PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment

Lymphoma | Solid Tumors

United States
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Pancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Pancreatic Acinar Cell Carcinoma | Locally Advanced Pancreatic Adenocarcinoma

United States
Samus Therapeutics, Inc.

Terminated

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States
NanoBio Corporation

Completed

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS) (SHaRCS)

Recurrent Herpes Labialis

United States
NanoBio Corporation

Completed

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)

Recurrent Herpes Simplex Labialis

United States
Samus Therapeutics, Inc.

Terminated

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Nobias Therapeutics, Inc.

Completed

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

22q11 Deletion Syndrome

United States, Canada
NanoBio Corporation

Unknown

NB-001 Treatment of Recurrent Herpes Labialis

Herpes Labialis

United States
Memorial Sloan Kettering Cancer Center
Samus Therapeutics, Inc.

Completed

PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Eisai Inc.

Completed

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Ewing Sarcoma | Rhabdomyosarcoma | Refractory or Recurrent Solid Tumors | Non-Rhabdomyosarcoma Soft Tissue Sarcoma

Spain, United Kingdom, Italy, France, Germany, Greece, Poland, Switzerland
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Stage Ib Lung Carcinoma | Stage IIA Lung Carcinoma | Stage IIIA Lung Carcinoma | Stage I Lung Cancer | Stage IA Lung Carcinoma AJCC V7

United States
Blokhin's Russian Cancer Research Center

Enrolling by invitation

Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients

Neoplasms | Carcinoma | Carcinoma, Squamous Cell | Neoplasms, Squamous Cell | Anus Neoplasms | Anus Diseases
Royal Marsden NHS Foundation Trust
Cancer Research UK; European Organisation for Research and Treatment of Cancer... and other collaborators

Unknown

International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT)

Squamous Cell Carcinoma of the Anus

United States, Australia, United Kingdom
Dwight Owen

Recruiting

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Stanford University

Completed

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

Lymphoma | Hodgkin Disease | Lymphoma, Hodgkin Disease | Lymphoma: Hodgkin

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Stage II Bladder Cancer AJCC v8 | Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall | Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia With PML-RARA

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Prostate Adenocarcinoma

United States, Canada
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Myeloid Neoplasm | Childhood Acute Promyelocytic Leukemia With PML-RARA

United States, Canada, Puerto Rico
Flemming Forsberg
National Cancer Institute (NCI)

Recruiting

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable...

United States, Norway

Search clinical trials for: Tricyclodecane-9-yl-xanthogenate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations